More on CTOR

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Citius Oncology (NQ:CTOR)
Delayed: 0.69 +0.02 (2.99%)
Prev. Close $0.67  
Open$0.69 
52 Wk High$ 
52 Wk Low$ 
Day High$0.69 
Day Low$0.68 
P/E N/A  
EPS$ 
Volume10,668 

Friends, Peers and Foes (?): CTXR, CAH, MCK, AMGN, FOLD (more...)

Jun 8, 2026 06:03 AM Form EFFECT CITIUS ONCOLOGY, INC.
Jun 4, 2026 04:30 PM Form SCHEDULE 13D/A CITIUS ONCOLOGY, INC. Filed by: Citius Pharmaceuticals, Inc.
Jun 1, 2026 04:46 PM Form 424B3 CITIUS ONCOLOGY, INC.
Jun 1, 2026 04:32 PM Form 8-K CITIUS ONCOLOGY, INC. For: Jun 01
Jun 1, 2026 07:01 AM Citius Oncology highlights phase 1 gynecologic cancer study data
Jun 1, 2026 07:00 AM Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
May 29, 2026 05:01 PM Form DEF 14C CITIUS ONCOLOGY, INC. For: May 29
May 29, 2026 04:33 PM Form S-3 CITIUS ONCOLOGY, INC.
May 26, 2026 08:00 AM Citius Oncology study data selected for ASCO presentation
May 26, 2026 08:00 AM Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
View All Articles

Entities mentioned with CTOR

View All Entities